Clinical lung cancer最新文献

{"title":"Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review","authors":"Anson Man Lok Yeung,&nbsp;James Chung Hang Chow","doi":"10.1016/j.cllc.2026.01.003","DOIUrl":"10.1016/j.cllc.2026.01.003","url":null,"abstract":"<div><div>Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon and aggressive malignancy, accounting for approximately 3% of all primary lung malignancies. Due to its rarity, the treatment paradigm for LCNEC is primarily derived from retrospective data from non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review synthesizes current evidence and discusses emerging treatment strategies. For medically fit patients with resectable disease, surgical resection, in particular lobectomy, should be offered, while stereotactic body radiation therapy can be reserved for medically inoperable patients. Adjuvant chemotherapy is suggested for most resected tumors, with SCLC regimens (eg, etoposide-cisplatin) associated with better outcomes; however, very early-stage tumors (stage IA) warrant individualized decision-making. There is currently no evidence supporting the use of adjuvant immunotherapy in LCNEC. The role of adjuvant radiotherapy, neoadjuvant therapy and prophylactic cranial irradiation in LCNEC remains undefined. For unresectable, locally advanced disease, concurrent chemoradiation with etoposide-cisplatin followed by consolidation durvalumab is recommended, although the optimal dose-fractionation and the duration of consolidation immunotherapy remain to be investigated. In metastatic disease, etoposide-platinum chemotherapy remains the first-line treatment, while targeted therapy can be considered if tumors harbor actionable genomic alterations. The potential benefit of immunotherapy is currently under investigation. While several second-line treatment options have been reported with modest efficacy, local ablative treatment has shown promise in oligometastatic LCNEC. Among the most promising emerging treatment strategies are DLL3-targeting therapies, buoyed by the recent success of tarlatamab in SCLC. The evolving role of molecular profiling in prognostication and treatment decision-making is also examined.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 85-97"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selpercatinib-Associated Nephropathy in RET Fusion-Positive Lung Cancer: A Case Successfully Managed With Dose Adjustment and Nephroprotective Therapy","authors":"Kohei Oe ,&nbsp;Koichi Saruwatari ,&nbsp;Yoshikazu Miyasato ,&nbsp;Yutaka Kakizoe ,&nbsp;Kaori Mochida ,&nbsp;Tsuguhiro Furukawa ,&nbsp;Kei Muramoto ,&nbsp;Kimitaka Akaike ,&nbsp;Yusuke Tomita ,&nbsp;Takuro Sakagami","doi":"10.1016/j.cllc.2025.12.001","DOIUrl":"10.1016/j.cllc.2025.12.001","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Nephrotic syndrome developed after selpercatinib in RET fusion-positive lung cancer</div></span></li><li><span>•</span><span><div>Renal biopsy revealed podocyte injury and mesangial IgA/IgM deposition</div></span></li><li><span>•</span><span><div>Proteinuria improved with selpercatinib dose reduction and ARB/SGLT2 use</div></span></li><li><span>•</span><span><div>Selpercatinib was successfully continued after nephroprotective intervention</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 1-5"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung SBRT Outcomes for Inoperable Early-Stage Lung Cancer Are Impaired in Patients With Solid Organ Transplants","authors":"Gregory M.M. Videtic ,&nbsp;Christopher W. Fleming ,&nbsp;Chandana A. Reddy ,&nbsp;Kevin L. Stephans","doi":"10.1016/j.cllc.2025.12.003","DOIUrl":"10.1016/j.cllc.2025.12.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize outcomes for solid organ transplant patients with medically inoperable early-stage lung cancer (ES-LC) treated with lung stereotactic body radiotherapy (SBRT).</div></div><div><h3>Methods</h3><div>We surveyed our institutional review board-approved prospective lung SBRT data registry from 2003 to 2023 for any transplant patients. Patterns of failure were assessed, as well as overall survival (OS) and disease-free survival (DFS). Univariate prognostic factors for OS and DFS were identified with Cox proportional hazards regression.</div></div><div><h3>Results</h3><div>Twenty-eight of 1976 definitively treated patients (1.4%) met study criteria. Median follow up was 12.4 months. Patient characteristics included: male (67.9%), median pack-years smoking of 34; median age 70.0 years; median Karnofsky Performance Status (KPS) 80. Organs transplanted were lung (57.2%), liver (21.4%), heart (21.4%). Tumor characteristics included: median size 2.4 cm; 85.7% with biopsy-proven cancer. Toxicity (any grade/type) was reported in 9 (32.1%) patients. Failure patterns were local 21.4%, lobar 7.1%, nodal 10.7% and distant 32.1%. First site of failure was distant in 50.0% patients. Median DFS and OS were 17.1 and 14.5 months, respectively. Increasing pack-years smoking was the only factor associated with increased disease failure on univariate analysis (UVA) (<em>P</em> = .0016). KPS and tumor size were significantly associated with OS on UVA and on multivariable analysis (<em>P</em> = .0075) and (<em>P</em> = .0181), respectively.</div></div><div><h3>Conclusions</h3><div>Organ transplant patients with inoperable ES-LC had higher than expected rates of local failure, decreased cancer control and poorer overall survival after SBRT. We hypothesize that transplant-associated immunosuppression promotes metastatic progression and a tumor biology resistant to SBRT.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 6-13"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial Response to Repotrectinib in ROS1-Rearranged Lung Squamous Cell Carcinoma: A Brief Report","authors":"Yukiko Yoshida ,&nbsp;Hajime Asahina ,&nbsp;Ken Kuwahara ,&nbsp;Hidenori Mizugaki ,&nbsp;Noriyuki Yamada ,&nbsp;Hiroshi Yokouchi ,&nbsp;Naohiro Nomura ,&nbsp;Yoshihiro Matsuno ,&nbsp;Satoshi Oizumi","doi":"10.1016/j.cllc.2026.01.002","DOIUrl":"10.1016/j.cllc.2026.01.002","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>ROS1 fusions are rare in lung squamous cell carcinoma (SCC), but they can occur, especially in non-smoking patients, highlighting the importance of comprehensive molecular testing even in SCC histology.</div></span></li><li><span>•</span><span><div>Repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor, demonstrated marked tumor regression and good tolerability as first-line treatment in an older adult patient with ROS1-rearranged lung SCC—the first such report to date.</div></span></li><li><span>•</span><span><div>This case suggests that ROS1-targeted therapies may provide clinical benefit in SCC harboring ROS1 rearrangements, emphasizing the need for molecular profiling to guide treatment decisions, regardless of tumor histology.</div></span></li><li><span>•</span><span><div>Even at a reduced dose, repotrectinib was effective and well tolerated in this older adult patient, suggesting dose adjustment may be considered based on individual patient characteristics.</div></span></li><li><span>•</span><span><div>Comprehensive molecular profiling, including ROS1 testing, should be part of routine diagnostic workup in non-smoking patients with NSCLC, including those with SCC histology, to identify potential actionable targets and optimize treatment strategy.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 80-84"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing Refusal of Adjuvant Chemotherapy in Non–Small Cell Lung Carcinoma","authors":"Claire Perez,&nbsp;Vikram Krishna,&nbsp;Drew Bolster,&nbsp;Kellie Knabe,&nbsp;Raffaele Rocco,&nbsp;Philicia Moonsamy,&nbsp;Harmik J. Soukiasian,&nbsp;Andrew R. Brownlee","doi":"10.1016/j.cllc.2026.01.008","DOIUrl":"10.1016/j.cllc.2026.01.008","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant chemotherapy is recommended for patients with resectable stage II and IIIA non–small cell lung cancer (NSCLC) and may be considered for high-risk stage I cases. Despite these guidelines, a significant number of patients decline treatment. We hypothesize that socioeconomic factors contribute to adjuvant chemotherapy refusal.</div></div><div><h3>Methods</h3><div>We queried the National Cancer Database (2010-2020) for patients with stage IB–IIIB NSCLC who underwent complete surgical resection. Patients were stratified by receipt of adjuvant chemotherapy. Multivariable logistic regression identified factors associated with chemotherapy refusal. Survival outcomes were analyzed using Kaplan–Meier curves.</div></div><div><h3>Results</h3><div>Of 47,481 eligible patients, 6701 (14.1%) refused adjuvant chemotherapy. Older patients (age &gt; 75) had higher odds of refusal (OR 5.2, 95% CI, 7.7-3.5). In contrast, Hispanic (OR 0.76, 95% CI, 0.90-0.63) and Black patients (OR 0.86, 95% CI, 0.95-0.78) were less likely to refuse. Higher comorbidity burden (Charlson-Deyo &gt; 3) and lack of insurance increased the likelihood of refusal (OR 1.32 and OR 1.3, respectively). Patients treated at academic centers were less likely to refuse than those at community centers (OR 0.88, 95% CI, 0.93-0.82). No sex-based differences were observed. Refusal was associated with reduced survival (HR 1.1, 95% CI, 1.1-1.01<strong>).</strong></div></div><div><h3>Conclusions</h3><div>Refusal of adjuvant chemotherapy in resectable NSCLC is influenced by age, comorbidities, insurance status, and treatment facility type. These findings highlight the need for targeted strategies to address treatment disparities and improve patient outcomes.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 108-116"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non–Small Cell Lung Cancer: A Case Report","authors":"Daisuke Morinaga ,&nbsp;Megumi Furuta ,&nbsp;Doppo Fukui ,&nbsp;Yuki Matsuura ,&nbsp;Yukiko Yoshida ,&nbsp;Shotaro Ito ,&nbsp;Yuta Takashima ,&nbsp;Hidenori Kitai ,&nbsp;Zenichi Tanei ,&nbsp;Jun Sakakibara-Konishi ,&nbsp;Satoshi Konno","doi":"10.1016/j.cllc.2026.01.012","DOIUrl":"10.1016/j.cllc.2026.01.012","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Amivantamab is a bispecific antibody targeting both <em>EGFR</em> and <em>MET,</em> with antibody-dependent cellular cytotoxicity activity and other immune-activating abilities.</div></span></li><li><span>•</span><span><div>It represents the first-in-class drug for the established standard therapy of NSCLC harboring <em>EGFR</em> exon 20 insertion mutations.</div></span></li><li><span>•</span><span><div>Real-world safety data on amivantamab remain limited, and vasculitis has not been previously reported.</div></span></li><li><span>•</span><span><div>We report a first case of amivantamab-associated vasculitis confirmed by lymph node biopsy, which resolved rapidly with corticosteroid treatment.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 117-120"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data","authors":"Gary C.N. Hettinger PhD ,&nbsp;Qi Long PhD ,&nbsp;Ravi B. Parikh MD","doi":"10.1016/j.cllc.2025.09.010","DOIUrl":"10.1016/j.cllc.2025.09.010","url":null,"abstract":"<div><h3>Background</h3><div>While substantial research has focused on first-line (1L) therapies for advanced-stage non-small cell lung cancer (aNSCLC), less is known about the effectiveness of second-line (2L) treatments following disease progression on 1L. The poor prognosis after 1L progression, limited guidance for 2L treatment, and constraints of clinical trials in addressing these questions underscore the need for real-world comparative effectiveness research.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis to compare real-world overall survival (rwOS) associated with 2L treatments among patients with disease progression during 1L. Eligible patients were selected from Flatiron Health’s nationwide electronic health record (EHR)-derived de-identified database. 1L and 2L treatments were categorized as chemotherapy-only (Chemo-alone), combination chemo- and immunotherapy (Chemo + Immuno), immunotherapy-only (IO-alone), targeted-alone therapy, or targeted-plus therapy. We used inverse probability of treatment weighting to adjust for extensive static and longitudinal patient-level confounding and compared rwOS using Kaplan-Meier curves and restricted mean survival time (RMST).</div></div><div><h3>Results</h3><div>Among patients previously treated with 1L Targeted therapy, those receiving 2L Targeted-alone therapy had longer life expectancies than those receiving a nontargeted (ΔRMST-36 + 2.61 months) or Targeted-plus regimen (ΔRMST-36 + 3.11 months). For patients progressing on 1L Chemo + Immuno, 2L Chemo + Immuno outperformed Chemo-alone (ΔRMST-36 + 2.98 months). Among patients progressing ≥1 year after initiating 1L IO-alone, 2L Chemo + Immuno again showed better life expectancy than Chemo-alone (ΔRMST-36 + 5.70 months).</div></div><div><h3>Conclusions</h3><div>Longitudinal real-world data can enhance assessment of 2L therapy effectiveness. After confounder adjustment, we found clinically meaningful survival differences by 2L choice. These findings underscore the importance of 2L treatment selection and the need for prospective validation.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 227-236.e12"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study","authors":"Ilaria Attili ,&nbsp;Gloria Pellizzari ,&nbsp;Luca Bertolaccini ,&nbsp;Carla Corvaja ,&nbsp;Davide Vacirca ,&nbsp;Mariano Lombardi ,&nbsp;Gianluca Spitaleri ,&nbsp;Pamela Trillo Aliaga ,&nbsp;Ester Del Signore ,&nbsp;Antonio Passaro ,&nbsp;Juliana Guarize ,&nbsp;Elena Guerini-Rocco ,&nbsp;Nicola Fusco ,&nbsp;Lorenzo Spaggiari ,&nbsp;Filippo de Marinis","doi":"10.1016/j.cllc.2025.09.015","DOIUrl":"10.1016/j.cllc.2025.09.015","url":null,"abstract":"<div><h3>Introduction</h3><div>In resected non-small cell lung cancer (NSCLC), molecular testing is currently limited to <em>EGFR</em> mutations and <em>ALK</em> rearrangements, as these guide approved adjuvant therapies. The role of next-generation sequencing (NGS), routinely used in metastatic NSCLC, remains unclear in earlier stages. The prevalence of other driver mutations and their impact on outcomes is not well established.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed clinical, molecular, and survival data from patients (pts) with stage IA-IIIB NSCLC (AJCC 8th) who underwent surgery and NGS at our Institute from January 2020 to December 2023. The primary endpoint was the prevalence of driver alterations. Exploratory analyses assessed recurrence, disease-free survival (DFS), overall survival (OS), and correlation with mutation status.</div></div><div><h3>Results</h3><div>Of 221 pts, 216 were eligible. Oncogenic alterations were found in 71% (73% in stage I), most commonly <em>KRAS</em> (30%) and <em>EGFR</em> (26%), followed by <em>MET</em> exon 14 skipping (6%), <em>BRAF</em> (4%), <em>HER2</em> exon 20 mutations (3%), and <em>ALK</em> and <em>RET</em> rearrangements (1%). Alteration distribution differed by sex and smoking status. With a median follow-up of 20 months, 36% of pts experienced recurrence, including 10 stage I cases. Median time to recurrence was 14 months. Recurrence rates were higher in pts with driver mutant NSCLC (39.6%) versus wild-type (29.6%). Highest recurrence was seen in pts with oncogenic fusion positive NSCLC and <em>EGFR</em> exon 20 insertions.</div></div><div><h3>Conclusions</h3><div>Driver mutations were detected in 70% of resected NSCLC, including stage I. The recurrence patterns observed support integrating NGS into early-stage management and exploring tailored adjuvant therapies, even for stage I tumors.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 259-268.e8"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Timing is Everything: Rethinking Immunotherapy Integration With Definitive Chemoradiation","authors":"Parth A. Desai,&nbsp;Martin J. Edelman","doi":"10.1016/j.cllc.2026.01.010","DOIUrl":"10.1016/j.cllc.2026.01.010","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 106-107"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series","authors":"Brook M. Lobsiger ,&nbsp;Ashley S. Huh-Brown ,&nbsp;Jacob S. Edmisson ,&nbsp;Brock O’Keefe ,&nbsp;Jinesh Gheeya ,&nbsp;Mark B. Botros ,&nbsp;Asrar A. AlAhmadi ,&nbsp;Misty D. Shields","doi":"10.1016/j.cllc.2025.09.008","DOIUrl":"10.1016/j.cllc.2025.09.008","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Tumor lysis syndrome (TLS) is a rare, potentially fatal toxicity to tarlatamab.</div></span></li><li><span>•</span><span><div>Monitoring for TLS in patients with bulky tumor burden and/or platinum-resistant SCLC is recommended.</div></span></li><li><span>•</span><span><div>Biomarkers to identify high-risk TLS in SCLC with tarlatamab are needed.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 2","pages":"Pages 210-213"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}